Dr. Barry is both an accomplished scientist and product developer, with over 20 years’ experience leading global development teams in large, mid-sized and start-up companies. Most recently John was VP of Research and  Development (R&D) at Miromatrix Medical, where he took an innovative cell therapy treatment for acute liver failure through to IND submission. Prior to this, he served as VP of R&D at Emergent Biosolutions and  built an international R&D team and pipeline of  products for use in the  emergency space. Previous roles include leading R&D at Baxter International’s Biosurgery  division, that included the development and launch of products for hemostatic control and soft and hard tissue repair. Dr. Barry received his PhD from the University of Nottingham (U.K.) for bone and cartilage repair, has published over 50 abstracts & journal articles, received recognition as a Fellow of the Royal Society of Chemistry and served as adjunct faculty at Loyola University School of Medicine (Chicago, IL). In addition, Dr. Barry has served as a principal investigator on grants, awards, and contracts from leading government agencies and non-profit organizations, including the National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), and U.S. Department of Defense (DoD).

‍